Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.

Iain J AbbottElke van GorpHugh CottinghamNenad Macesic Steven C Wallis Jason Alexander Roberts Joseph Meletiadis Anton Y Peleg

Published in: The Journal of antimicrobial chemotherapy (2022)

Bladder infection modelling supports oral ciprofloxacin activity against E. coli with low-level resistance (ciprofloxacin MIC ≤ 1 mg/L) when using high dose therapy (750 mg 12 hourly).

Keyphrases

escherichia coli
pseudomonas aeruginosa
high dose
spinal cord injury
low dose
biofilm formation
cystic fibrosis
urinary tract
mesenchymal stem cells
candida albicans